Plain-English translation of NCT06776419 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Fabry disease is a rare genetic condition where harmful substances build up in cells throughout the body, especially affecting the heart and kidneys. This study uses advanced imaging (PET/CT scans and MRI) and blood tests to detect early heart damage in Fabry patients compared to healthy people, so doctors can start treatment sooner and prevent serious complications.
Right now, doctors struggle to know which Fabry patients need treatment immediately and which can wait safely. Recent research shows that starting this medication early, before the heart is severely damaged, works much better than starting it late — but we need better ways to catch heart damage early so patients don't miss their window for treatment.
You likely qualify if…
You likely don't qualify if…
You will have two imaging tests: an MRI scan of your heart (like a detailed photograph) and a PET/CT scan where you receive a small amount of tracer substance to show how your heart is working. You'll also have blood samples taken. For the PET/CT, your heart will be gently stressed (either by medication or mild exercise) to see how it responds. The visits will take several hours total, though the exact number of visits isn't specified in this trial description.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Denmark